Allarity Therapeutics (NASDAQ:ALLR – Get Free Report) and Cardio Diagnostics (NASDAQ:CDIO – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, risk, profitability and valuation.
Profitability
This table compares Allarity Therapeutics and Cardio Diagnostics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Allarity Therapeutics | N/A | -112.05% | -64.89% |
| Cardio Diagnostics | -39,674.18% | -67.51% | -62.27% |
Analyst Ratings
This is a breakdown of current recommendations and price targets for Allarity Therapeutics and Cardio Diagnostics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Allarity Therapeutics | 1 | 0 | 1 | 0 | 2.00 |
| Cardio Diagnostics | 1 | 0 | 0 | 0 | 1.00 |
Volatility & Risk
Allarity Therapeutics has a beta of 0.23, indicating that its stock price is 77% less volatile than the S&P 500. Comparatively, Cardio Diagnostics has a beta of 2.94, indicating that its stock price is 194% more volatile than the S&P 500.
Institutional & Insider Ownership
11.5% of Allarity Therapeutics shares are owned by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are owned by institutional investors. 0.1% of Allarity Therapeutics shares are owned by company insiders. Comparatively, 13.3% of Cardio Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares Allarity Therapeutics and Cardio Diagnostics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Allarity Therapeutics | N/A | N/A | -$24.51 million | ($0.59) | -1.98 |
| Cardio Diagnostics | $40,000.00 | 93.79 | -$8.38 million | ($3.74) | -0.55 |
Cardio Diagnostics has higher revenue and earnings than Allarity Therapeutics. Allarity Therapeutics is trading at a lower price-to-earnings ratio than Cardio Diagnostics, indicating that it is currently the more affordable of the two stocks.
Summary
Cardio Diagnostics beats Allarity Therapeutics on 7 of the 13 factors compared between the two stocks.
About Allarity Therapeutics
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.
About Cardio Diagnostics
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
Receive News & Ratings for Allarity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allarity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
